Alkem Medtech, the medical devices arm of Alkem Laboratories, has agreed to acquire a 55% controlling stake in Occlutech International AB for €99.4 million. The deal gives Alkem entry into the fast-growing structural heart intervention market, adding Occlutech’s portfolio of minimally invasive occluder devices for congenital heart defects, stroke prevention, and heart failure to its global offerings.
Glimpse:
The transaction values Occlutech at a significant premium and includes its established range of atrial septal defect (ASD), patent foramen ovale (PFO), left atrial appendage (LAA), and ventricular septal defect (VSD) occluders. Alkem will leverage Occlutech’s strong European regulatory approvals and commercial presence to accelerate international expansion, while Occlutech benefits from Alkem’s manufacturing scale and emerging-market reach. The acquisition marks Alkem’s largest medtech move yet and signals India’s growing ambition in high-value cardiovascular devices.
Alkem Medtech, the fast-growing medical devices division of Indian pharma major Alkem Laboratories, has signed a definitive agreement to acquire a 55% majority stake in Occlutech International AB, a Switzerland-headquartered leader in structural heart occluder devices. The deal, valued at €99.4 million (approximately ₹900 crore), was announced in early 2026 and is subject to customary regulatory approvals and closing conditions.
Occlutech specializes in minimally invasive devices used to close abnormal openings in the heart and prevent stroke-causing blood clots. Its flagship products include the Occlutech ASD, PFO, LAA, and VSD occluders, which are CE-marked and commercially available in Europe, parts of Asia, Latin America, and select emerging markets. The company has a strong track record of innovation, clinical evidence, and physician trust in interventional cardiology.
For Alkem, the acquisition provides immediate entry into the high-margin, fast-growing structural heart intervention segment—currently dominated by global giants. It complements Alkem Medtech’s existing portfolio in orthopaedics, urology, critical care, and consumables, while opening new export avenues and strengthening its position in regulated markets. Post-acquisition, Occlutech will continue to operate under its brand with existing management, supported by Alkem’s manufacturing scale, cost efficiencies, and distribution strength in India and other high-growth regions.
The transaction reflects Alkem’s aggressive push to transform from a generics-focused pharma company into a diversified healthcare player. It also underscores India’s rising outbound medtech M&A activity as domestic firms seek technology, IP, and global market access to compete at scale.
Closing is expected in the coming months, pending antitrust and foreign investment clearances.
“This acquisition accelerates our journey to become a global medtech player with differentiated, high-impact cardiovascular solutions.”
By
HB Team
Related News
